A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2912 participants.

Also called NCT05952856

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,912 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05952856
  • EU CT 2022-502777-42-01
  • WHO UTN U1111-1285-4164
  • jRCT jRCT2031230320
Other papers using this trial's data
  • A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide The New England journal of medicine, 2026-02-05 DOI, PubMed 41879224

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, China, Colombia, Germany, Israel, Italy, Japan, Mexico, South Africa, South Korea, Spain, Taiwan, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05952856. Randomized; triple masking; primary purpose treatment. Start 2023-08-10 (actual); primary completion 2025-07-28 (actual). Results posted on 2026-08-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
Condition
Hypercholesterolemia
Intervention (Drug)
Enlicitide Decanoate
Intervention (Drug)
Placebo
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct05952856
Content hash
53895bb22e72143c4122cee4d4a82689353d0fc7077c8c0a803f8dd8eb6573e5